CClinicalTrials.gg
RecruitingNCT07615257managing psychUpdated May 29, 2026

Managing Psychological Distress Through Mindfulness-based CBT to Evaluate Its Effectiveness on Self-compassion Among Psoriasis Patients:The Mediating Role of Mental Health Locus of Control

An interventional study of Mindfulness-Based Cognitive Therapy (MBCT) and Usual Care in Psoriasis, sponsored by Islamia University of Bahawalpur. Recruiting at 1 site in Pakistan. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Islamia University of Bahawalpur · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Feb 2025, registered May 2026).
  • Started Feb 2025; still recruiting 1 year 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
25 Years to 75 Years
Sex
All
01

Study summary

Your research study is about evaluating the effectiveness of **Mindfulness-Based Cognitive Therapy (MBCT)** in reducing psychological distress among psoriasis patients and improving their self-compassion and Mental Health Locus of Control (MHLC).

The study highlights that psoriasis patients often suffer not only from physical symptoms but also from psychological problems such as stress, anxiety, depression, self-judgment, and low self-compassion. Traditional treatments mainly focus on physical symptoms and may not fully address these emotional and psychological difficulties.

To address this gap, the study proposes MBCT as a psychological intervention that combines mindfulness practices with cognitive therapy techniques. MBCT helps patients become more self-aware, reduce negative thinking, and develop self-compassion without self-judgment. The research also explores MHLC, which refers to how much control individuals believe they have over their health outcomes.

The study aims to investigate whether MBCT can:

  • Reduce psychological distress, anxiety, depression, and stress levels
  • Improve self-compassion among psoriasis patients
  • Shift patients' locus of control from external to internal
  • Enhance emotional well-being and coping mechanisms

The research follows a quantitative experimental design conducted in phases. Initially, baseline levels of distress, MHLC, and self-compassion will be assessed. Later, MBCT interventions will be implemented and evaluated for effectiveness.

Overall, the study seeks to contribute to integrated psoriasis care by emphasizing the importance of psychological health alongside physical treatment, ultimately improving patients' quality of life and therapeutic outcomes.

02

Conditions studied

  • Psoriasis

Browse trials for

03

In context

Psoriasis

1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.

This study's planned enrollment of 128 is above the median of 70 across 1,447 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

Islamia University of Bahawalpur is the lead sponsor of 15 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosed psoriasis patients
  • Age between 18 and 65 years
  • Both male and female participants
  • Participants willing to provide informed consent
  • Participants experiencing psychological distress

Exclusion criteria

Exclusion Criteria:

  • Under the age of 18 years will be excluded.
  • Patients with severe psychiatric disorders
  • Patients currently receiving other psychological therapies
  • Patients with serious medical or neurological conditions
  • Participants unwilling to continue the intervention sessions
  • Patients with cognitive impairment affecting participation
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Participants in this group will receive Mindfulness-Based Cognitive Therapy (MBCT) intervention.

    Behavioral: Mindfulness-Based Cognitive Therapy (MBCT)

  • Experimental
    Control Group

    Participants in this group will receive usual care without MBCT intervention.

    Other: Usual Care

Interventions

  • BehavioralMindfulness-Based Cognitive Therapy (MBCT)

    Mindfulness-Based Cognitive Therapy (MBCT) will be administered to psoriasis patients to reduce psychological distress and improve self-compassion and mental health locus of control. The intervention includes mindfulness practices and cognitive behavioral techniques delivered in structured sessions.

  • OtherUsual Care

    Participants in the control group will receive usual care without Mindfulness-Based Cognitive Therapy intervention.

06

What researchers measure

Primary outcomes

  1. Reduction in Psychological Distress

    To evaluate the effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in reducing psychological distress among psoriasis patients.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Department of Dermatologist Sheikh Zayed Hospital Rahim Yar Khan
    Rahim Yar Khan, Punjab Province 64200, Pakistan
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07615257
Lead sponsor
Islamia University of Bahawalpur
Responsible party
Rafia Ghaffar (PhD scholar, Islamia University of Bahawalpur) — Principal investigator
First posted
May 29, 2026
Start date
Feb 5, 2025
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 12, 2026 (estimated)
Last update
May 29, 2026

Study contacts

Rafia Ghaffar, Phd
Contact
rafiaghaffar1@gmail.com
923336096376

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion